Abstract
Targeted oncological therapy opens new options for the treatment of non-small-cell lung cancer (NSCLC). The therapy is mostly well tolerated, with the most common form of toxicity being papulopustular eruption.
The authors report their experiences with erlotinib therapy and adverse skin reactions in 333 NSCLC patients.